Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0305-7372(82)80089-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience.
J Cancer
October 2015
1. Department Internal Medicine, Medical Oncology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland ; 2. Lung Tumor Center, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
Background: Randomized trials established topotecan and the combination of adriamycin, cyclophosphamide and vincristine (ACO) as second-line therapy options for small-cell lung cancer. We retrospectively evaluated the outcome of SCLC patients undergoing second-line chemotherapy.
Patients And Methods: 92 consecutive patients with a diagnosis of SCLC between 2000 and 2010 were analyzed.
Background: Small-cell lung cancer is a disease affecting mostly elderly persons. Therefore, many patients show marked comorbidity and intensive chemotherapy is not possible in such patients. As the disease is most often in the 'extensive' stage at diagnosis, the therapy option is only palliative.
View Article and Find Full Text PDFAcute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
Ann Oncol
September 2000
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Germany.
Background: Evidence is recently accumulating that the novel BEACOPP (bleomycin (B), etoposide (E), adriamycin (A), cyclophosphamide (C), vincristine (O), procarbazine (P), prednisone (P)) chemotherapy is a highly effective treatment for advanced stage Hodgkin's disease. Two dose variants of BEACOPP are currently tested in a phase III randomized multicenter trial of the GHSG. To enable more extensive testing of BEACOPP we characterized its practicability regarding schedule adherence, acute hematotoxicity and need for supportive treatment.
View Article and Find Full Text PDFChemotherapeutic induction of long-term remission in metastatic medulloblastoma.
J Neurooncol
April 1997
University of Freiburg Medical Center, Department of Internal Medicine I (Hematology-Oncology), Germany.
The treatment of extraneural metastatic medulloblastoma is mainly a domain of chemotherapy. Although previous results were promising, the overall poor prognosis high relapse rates and the still unknown ideal combination of chemotherapeutic agents leave many questions open. In this study, the effectiveness of previously used chemotherapeutic agents for the treatment of metastatic medulloblastoma is reviewed, and the effectiveness and complexity of emerging new treatment strategies including high-dose chemotherapy with bone marrow and peripheral blood stem-cell transplantation are discussed.
View Article and Find Full Text PDFDose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Ann Oncol
January 1997
Department of Internal Medicine, University of Freiburg Medical Center, Freiburg im Breisgau, Germany.
Background: We conducted a phase I/II trial to assess the feasibility and activity of VIP-E chemotherapy in small-cell lung cancer. End-points were treatment-related morbidity and mortality, response to treatment. duration of response, and survival.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!